LPL Financial
APRE icon

LPL Financial’s Aprea Therapeutics APRE Stock Holding History

LPL Financial’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Sell
16,052
-5,000
-24% -$4.17K ﹤0.01% 6153
2026
Q1 		$16.1K Sell
21,052
-5,000
-19% -$3.93K ﹤0.01% 5893
2025
Q4 		$22.2K Buy
26,052
+10,000
+62% +$12.3K ﹤0.01% 5802
2025
Q3 		$23.7K Sell
16,052
-1,000
-6% -$1.65K ﹤0.01% 5725
2025
Q2 		$28.8K Buy
17,052
+1,000
+6% +$1.71K ﹤0.01% 5427
2025
Q1 		$32.7K Hold
16,052
– – ﹤0.01% 5204
2024
Q4 		$52.8K Buy
+16,052
New +$53.6K ﹤0.01% 5097

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

LPL Financial's APRE Position: Q2 2026 in Review

LPL Financial reduced its Aprea Therapeutics (APRE) stake by 24% in Q2 2026, selling an estimated $4.17K and leaving 16,052 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6153.

LPL Financial first reported a position in APRE in Q4 2024 and has held it in 7 quarters since. The position peaked at $52.8K in Q4 2024. 6 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • LPL Financial held 16,052 shares of Aprea Therapeutics worth $12.9K as of Q2 2026.
  • LPL Financial sold 5,000 Aprea Therapeutics shares in Q2 2026, an estimated $4.17K.
  • Aprea Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #6153 holding.
  • LPL Financial first reported a position in Aprea Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • LPL Financial's Aprea Therapeutics position peaked at $52.8K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.